UNITE4TB
A consortium of 30 partners from 13 countries is working together to advance anti-tuberculosis (TB) science and to enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide. The LMU University Hospital Munich and the German Center for Infection Research (DZIF) take on a central role in this consortium named "Academia and industry united innovation and treatment for tuberculosis", or UNITE4TB for short. The aim of UNITE4TB is to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB.
UNITE4TB is a project of the "IMI-AMR-Accelerator"—a public-private collaboration of the "Innovative Medicines Initiative" (IMI).